Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia.

Linger RM, DeRyckere D, Brandão L, Sawczyn KK, Jacobsen KM, Liang X, Keating AK, Graham DK.

Blood. 2009 Sep 24;114(13):2678-87. doi: 10.1182/blood-2009-03-209247. Epub 2009 Jul 30. Retraction in: Blood. 2012 Aug 16;120(7):1533.

2.

Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia.

Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, Brandão LN, Winges A, Sawczyn KK, Liang X, Keating AK, Tan AC, Earp HS, Graham DK.

Blood. 2013 Aug 29;122(9):1599-609. doi: 10.1182/blood-2013-01-478156. Epub 2013 Jul 16.

3.

Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis.

Sarvaiya PJ, Schwartz JR, Hernandez CP, Rodriguez PC, Vedeckis WV.

Am J Hematol. 2012 Oct;87(10):969-76. doi: 10.1002/ajh.23283. Epub 2012 Jul 5.

4.

Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS).

Krause S, Pfeiffer C, Strube S, Alsadeq A, Fedders H, Vokuhl C, Loges S, Waizenegger J, Ben-Batalla I, Cario G, Möricke A, Stanulla M, Schrappe M, Schewe DM.

Blood. 2015 Jan 29;125(5):820-30. doi: 10.1182/blood-2014-06-583062. Epub 2014 Nov 26.

5.

UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.

Christoph S, Deryckere D, Schlegel J, Frazer JK, Batchelor LA, Trakhimets AY, Sather S, Hunter DM, Cummings CT, Liu J, Yang C, Kireev D, Simpson C, Norris-Drouin J, Hull-Ryde EA, Janzen WP, Johnson GL, Wang X, Frye SV, Earp HS 3rd, Graham DK.

Mol Cancer Ther. 2013 Nov;12(11):2367-77. doi: 10.1158/1535-7163.MCT-13-0040. Epub 2013 Aug 30.

6.

GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.

Shiozawa Y, Pedersen EA, Taichman RS.

Exp Hematol. 2010 Feb;38(2):132-40. doi: 10.1016/j.exphem.2009.11.002. Epub 2009 Nov 14.

7.

Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia.

Lee-Sherick AB, Eisenman KM, Sather S, McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J, Martinson H, Cannon C, Keating AK, Earp HS, Liang X, DeRyckere D, Graham DK.

Oncogene. 2013 Nov 14;32(46):5359-68. doi: 10.1038/onc.2013.40. Epub 2013 Mar 11.

8.

Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.

Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK.

Mol Cancer Ther. 2010 May;9(5):1298-307. doi: 10.1158/1535-7163.MCT-09-0707. Epub 2010 Apr 27.

9.

GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.

Meng X, Matlawska-Wasowska K, Girodon F, Mazel T, Willman CL, Atlas S, Chen IM, Harvey RC, Hunger SP, Ness SA, Winter SS, Wilson BS.

Leukemia. 2011 Jul;25(7):1135-46. doi: 10.1038/leu.2011.50. Epub 2011 Apr 15.

10.

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM.

Blood. 2003 May 1;101(9):3597-605. Epub 2003 Jan 16.

11.

Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia.

Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, Jordan CT, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS, Graham DK.

Oncotarget. 2015 Mar 30;6(9):6722-36.

12.

The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.

Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ.

Haematologica. 2011 Jan;96(1):69-77. doi: 10.3324/haematol.2010.026997. Epub 2010 Oct 15.

13.

Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.

Lühl NC, Zirngibl F, Dorneburg C, Wei J, Dahlhaus M, Barth TF, Meyer LH, Queudeville M, Eckhoff S, Debatin KM, Beltinger C.

Haematologica. 2014 Jun;99(6):1050-61. doi: 10.3324/haematol.2013.087205. Epub 2014 Apr 3.

14.

Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.

Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, Dellinger MT, Lorens JB, Brekken RA.

Cancer Res. 2015 Sep 15;75(18):3699-705. doi: 10.1158/0008-5472.CAN-14-2887-T. Epub 2015 Jul 23.

15.

Targeted therapy with MXD3 siRNA, anti-CD22 antibody and nanoparticles for precursor B-cell acute lymphoblastic leukaemia.

Satake N, Duong C, Chen C, Barisone GA, Diaz E, Tuscano J, Rocke DM, Nolta J, Nitin N.

Br J Haematol. 2014 Nov;167(4):487-99. doi: 10.1111/bjh.13066. Epub 2014 Sep 8.

16.
17.

Targeting of the deubiquitinase USP9X attenuates B-cell acute lymphoblastic leukemia cell survival and overcomes glucocorticoid resistance.

Zhou M, Wang T, Lai H, Zhao X, Yu Q, Zhou J, Yang Y.

Biochem Biophys Res Commun. 2015 Apr 3;459(2):333-9. doi: 10.1016/j.bbrc.2015.02.115. Epub 2015 Feb 28.

PMID:
25735983
18.

Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase.

Keating AK, Salzberg DB, Sather S, Liang X, Nickoloff S, Anwar A, Deryckere D, Hill K, Joung D, Sawczyn KK, Park J, Curran-Everett D, McGavran L, Meltesen L, Gore L, Johnson GL, Graham DK.

Oncogene. 2006 Oct 5;25(45):6092-100. Epub 2006 May 1.

PMID:
16652142
19.

Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.

Shi PJ, Xu LH, Lin KY, Weng WJ, Fang JP.

J Hematol Oncol. 2016 Feb 18;9:12. doi: 10.1186/s13045-016-0241-x.

20.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, Degryse S, Canté-Barrett K, Briot D, Clappier E, Lammens T, De Moerloose B, Benoit Y, Poppe B, Meijerink JP, Cools J, Soulier J, Rabbitts TH, Taghon T, Speleman F, Van Vlierberghe P.

Blood. 2014 Dec 11;124(25):3738-47. doi: 10.1182/blood-2014-05-574566. Epub 2014 Oct 9.

Supplemental Content

Support Center